@article{fdd54180965d49fd893dcdd1c5b312fb,
title = "A Non-Profit Approach to Address Foreign Dependence of Generic Drugs",
abstract = "The COVID-19 pandemic has revealed the vulnerability of the US generic drug supply chain to foreign production. Many policies have been proposed to mitigate this vulnerability. In this article, we argue that nonprofit drug manufacturers have the potential to make important contributions.",
keywords = "Drug Supply Chain, Foreign Dependence, Generic Drug, Non-profit, Prescription Drug Manufacturing",
author = "Dan Liljenquist and Ge Bai and Ameet Sarpatwari and Anderson, {Gerard F.}",
note = "Funding Information: Mr. Liljenquist is Senior Vice President and Chief Strategy Officer of Intermountain Healthcare and the Chairman of Civica Rx, a non-profit drug manufacturer; Dr. Anderson reports grants from Arnold Ventures during the conduct of the study; Dr. Sarpatwari reports grants from Arnold Ventures and the Open Society Foundations during the writing of the work, and personal fees from West Health outside the submitted work. Dr. Bai received funding from Arnold Ventures and consulting fee from Council for Informed Drug Spending Analysis. Publisher Copyright: {\textcopyright} 2021 The Author(s).",
year = "2021",
doi = "10.1017/jme.2021.6",
language = "English (US)",
volume = "49",
pages = "30--33",
journal = "Journal of Law, Medicine and Ethics",
issn = "1073-1105",
number = "1",
}